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Abstract
Backgrounds: Autism is a developmental disorder characterized by social and emotional deficits, language
impairments and stereotyped behaviors that manifest in early postnatal life. This study aims to compare the
relative concentrations of essential fatty acids (Linoleic and a- linolenic), their long chain polyunsaturated fatty
acids and phospholipids in plasma of autistic patients from Saudi Arabia with age-matching controls.
Methods: 25 autistic children aged 3-15 years and 16 healthy children as control group were included in this
study. Relative concentration of essential fatty acids/long chain polyunsaturated fatty acids and omega-3/omega-6
fatty acid series together with phosphatidylethanolamine, phosphatidylserine and phosphatidylcholine were
measured in plasma of both groups.
Results: Remarkable alteration of essential fatty acids/long chain polyunsaturated fatty acids, omeg-3/omega-6 and
significant lower levels of phospholipids were reported. Reciever Operating characteristics (ROC) analysis of the
measured parameters revealed a satisfactory level of sensitivity and specificity.
Conclusion: Essential fatty acids/long chain polyunsaturated fatty acids and omeg-3/omega-6 ratios,
phosphatidylethanolamine, phosphatidylserine and phosphatidylcholine could be used as potential biomarkers that
point to specific mechanisms in the development of autism and may help tailor treatment or prevention strategies.
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Introduction
Autism is the most commonly studied of a spectrum of
developmental disorders that are believed to be neuro-
biologically based but which, at this point, for lack of
good biomarkers, are defined purely by behavior [1].
The number of cases has risen dramatically, and various
hypotheses have been put forward to explain this phe-
nomenon. Early estimates of the prevalence of this spec-
trum of disorders identified not less than 10 in 10,000
individuals as possessing some form of autism [2].
Autistic symptoms may also differ qualitatively from
symptoms that characterize other disorders. Attention
deficit, hyperactivity, and impulsivity are common in
children with autism. Children with autism also have
the ability to hyperfocus on activities of interest to
them, such as spending hours twirling a string or read-
ing a book.
Essential fatty acids (EFAs) taken in diets mediate
brain functions and structures during development and
are involved in many brain related disorder like autism.
Fatty acids are commonly classified as saturated, mono-
unsaturated, and polyunsaturated (PUFA) fatty acids,
depending on the chemical structure and the length of
the chain that can vary from 12 to 26 carbon bonds.
Two types of PUFAs are EFA: linoleic acid (LA: 18:2, n-
6) and a-linolenic acid (ALA: 18:3, n-3). The brain can-
not distinguish among longer chain fatty acids that have
been synthesized in the brain, and those that have been
obtained from diet and crossed the blood-brain barrier.
Clearly, the blood-brain barrier is a key to the bioavail-
ability of brain EFA and PUFAs.
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branes are the phospholipids that contain fatty acids.
The brain phospholipids are exceptionally rich in
PUFAs [3,4] and in contrast to other bodily tissue, a
unique feature of neurons is the smaller amounts of
t h ep r e c u r s o r sL Aa n dA L Aa n dt h eh i g h e ra m o u n t so f
their metabolites: arachidonic acid (AA: 20:4, n-6) and
docasahexaenoic acid (DHA: 22:6, n-3) [3-6]. The two
major PUFAs in all vertebrates are AA and DHA [7]
and account for 20% of the dry brain weight [3,8].
DHA is known to be involved in cell signaling and cell
proliferation [9] and has an important structural role
in the brain [10], whilst AA is crucial for brain growth.
Eicosapentaenoic (EPA: 20:5, n-3) seemingly has no
structural role, but it is considered vital for the regula-
tion of brain function [10]. LysoPC is a preferred car-
rier form of DHA to the brain [11]. On the other
hand, there is evidence that entry of PUFAs into brain
microvessels involves phospholipase A2 (PLA2) and
lipoprotein- induced methylation of phosphatidyletha-
nolamine (PE) [12].
Abnormalities in the fatty acid compositions of
phospholipids, the major constituents of cell mem-
branes, have been implicated in several neurodevelop-
mental disorders that manifest with psychiatric
symptoms. For example, in schizophrenia, changes of
red blood cell (RBC) membrane phospholipids such
as deficiencies in n-3 PUFAs have been reported
[13-16]. Indeed, supplementing diets with fish oil was
shown to correct these deficiencies and lead to
improvements in the symptom scores of schizophre-
nic patients [17]. Similarly, defects of fatty acids and
phospholipids have recently been reported in autism
subjects, including not only reduced levels of n-3
PUFAs, but also increased levels of saturated fatty
acids in the RBC membrane [18] or in plasma [3, El-
Ansary A, Ben Bacha A, Al-Ayadhi L: Plasma fatty
acids as diagnostic markers ina u t i s t i cp a t i e n t sf r o m
Saudi Arabia, Submitted]. Further evidence from Bell
et al. (2004) [19] suggested that decreased levels of
AA, docosatetraenoic acid (DTA) and DHA in RBC
membranes from autism subjects could be caused by
increased activity of RBC type IV PLA2, suggesting
that altered metabolism of phospholipids may occur
in autism [19].
This information initiates our interest to evaluate the
plasma levels of phosphatidyl choline (PC), phosphati-
dylserine (PS) and PE as three important members of
brain phospholipids in autistic patients. Moreover the
relative amounts of EFA and PUSFA will be measured
in a trial to highlight the possibility of using these lipid-
related parameters as diagnostic markers.
Materials and methods
Reagents and chemicals
Chloroform and methanol used for extraction, ammonia
(NH3) and water methanol for the mobile phase were
99% HPLC grade and obtained from Sigma-Aldrich
(Taufkirchen, Germany). PC, PS and PE were obtained
from Fluka, Sigma-Aldrich (Taufkirchen, Germany).
Subjects and methods
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki (Edinburgh, 2000).
All subjects enrolled in the study (25 autistics and 16
controls) had written informed consent provided by
their parents and assented to participate if developmen-
tally able. They were enrolled through the ART Center
(Autism Research & Treatment Center) clinic. The ART
Center clinic sample population consisted of children
diagnosed on the autism spectrum (ASD). The diagnosis
of ASD was confirmed in all subjects using the Autism
Diagnostic Interview-Revised (ADI-R) and the Autism
Diagnostic Observation Schedule (ADOS) and 3DI
(Developmental, dimensional diagnostic interview). The
ages of all autistic children participate between the ages
of 4 and 12 years old. All were simplex cases. All are
negative for fragile x gene study. The control group
recruited from well baby clinic at king Khaled university
hospital with mean age 4-11 years old. Subjects were
excluded from the investigation if they had dysmorphic
features, or diagnosis of Fragile X or other serious neu-
rological (e.g., seizures), psychiatric (e.g., bipolar disor-
der) or known medical conditions. All participants were
screened via parental interview for current and past phy-
sical illness. Children with known endocrine, cardiovas-
cular, pulmonary, liver, kidney or other medical disease
were excluded from the study.
Samples collection
Blood samples were collected in the morning following
at least 10 hour period of fasting. Plasma was collected
using standard clinical practices and stored at -80°C
until thawed for analysis.
Lipid extraction and chromatography
- Measurement of EFA and PUSFA: Plasma (200 μl)
lipids were extracted in the presence of internal stan-
dards and FA methylated using 3N methanolic HCL in
sealed vials under nitrogen and incubated at 100C for
45 min. The methyl esters of free fatty acids were
extracted with hexane, and the fatty acid composition of
the extract was analyzed on a gas chromatograph (Helw-
lett-Packard 5890 series II plus, HP analytical Direct,
Wilmington, DE), equipped with a flame ionization
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umn( Omegawax 250# 2-4136, Supelco). The helium gas
flow rate was 1.2 ml/min, with a split/flow ratio of 50:1.
Oven temperature was held at 205°C. The injector and
detector temperatures were 260 and 262°C, respectively.
Two internal standards, C15:0 and C23:0, were added
during analysis. Fatty acids were identified via compari-
son of retention times with authentic standards [20].
- Phospholipids Measurement: Phospholipid separation
was performed on a Kaneur Maxi Star HPLC system
with four solvent lines, a degasser SEDEX 55 evaporat-
ing light detector (SEDEX 55 Lichtstreu detector, S.E.D.
E.E., France) which was coupled with Apex M625 soft-
ware (Autochrom, USA). As the nebulizing gaz, N2 was
used at a flow rate of 4l/min, and a nebulizing tempera-
ture of 40°C. The gain was set at 8 and 2.0 bar N2.
A 125 × 4.0 mm Si-60 column with 5 μm particle dia-
meter (Lichrosher) was used. The elution program was
a linear gradient with 80:19.5:0.5 (V/V) chloroform:
methanol: water: ammonia (NH3) at 22 min and the col-
umn was allowed to equilibrate until the next injection
at 27 min. The injection volume was 50 μl. A liquid
phase extraction procedure adapted from the method
described by Bligh and Dyer (1959) was used to extract
the serum samples.
Briefly, 50 μl of sample was diluted with 750 μld e i o -
nized water and mixed well. Then 2 ml of methanol and
1 ml of chloroform were added to the sample and
mixed well. Then the mixture was homogenized (Rotary
mixture 34526, Snijders) for 15 min. The mixture was
centrifuged for 5 min by 4000 rpm.
Statistical analysis
An SPSS computer program was used. Results were
expressed as mean ± S.D. and all statistical comparisons
were made by means of independent t-Test with P ≤
0.005 was considered significant. Reciever Operating
Characteristics analysis (ROC) was performed. Area
under the curve, cutoff values together with degree of
specificity and sensitivity were calculated. ROC curves
are constructed by plotting the false positive rate (i.e.
100-specificity) against the true positive rate (i.e. sensitiv-
ity). These have been widely accepted as standard tools
for evaluating the performance of diagnostic tests. The
AUC is an overall summary of diagnostic accuracy, incor-
porating both components of accuracy, i.e., sensitivity
and specificity, into a single measure. The AUC has been
widely used as a quantitative index of the performance of
a biomarker in a variety of applied fields; it is a simple
and convenient overall measure of diagnostic test [21,22].
Results and Discussion
EFAs and their long chain PUFAs are of critical impor-
tance in fetal growth and development [23-26]. These
fatty acids are the precursors of eicosanoids and are
essential constituents of the membrane lipids that main-
tain cellular and organelle integrity and important intra-
cellular mediators of gene expression [27-29].
Table 1 shows that autistic patients of Saudi Arabia
recorded a remarkable higher LA/AA and ALA/DHA
ratios compared to age-matching controls. It appears
that the same enzymes catalyze the conversion of both
omega-6 and omega-3 fatty acid precursors into PUFAs.
As reported by Pawlosky et al (2001) [30], the first step
of the conversion process, ALA to EPA, is the rate-lim-
iting step, with only 0.2% of ALA converted to EPA.
The enzyme responsible for this conversion also con-
verts docosapentaenoic acid (DPA) to the final product
DHA but at a much higher rate (37%), suggesting that
the enzyme has a low affinity for ALA. These enzymes
are regulated by a negative feedback loop, suggesting
that the dietary balance of different fatty acids is impor-
tant [31]. The desaturation enzymes are only fully
induced when levels of PUFAs are low, whereas if there
is an adequate level of fatty acids, these desaturases are
suppressed. Based on these information, we can suggest
that a poorer ability to convert 18-carbon FA (LA and
ALA) to their longer and more highly unsaturated deri-
vatives could be considered in autistic patients of Saudi
Arabia. This explanation could be supported through
considering the previous work of Herault et al. (1993)
[32] who detected a site linked to autism located on
chromosome 11q22-23, in the viciny of the gene for
delta-6 desaturase, which is the enzyme first involved in
the production of PUFA-long chain derivatives of both
(n-3) and (n-6) series [33]. The obtained results could
find a support by the previous work of Richardson and
Ross (2000) [16] in which an impairment of PUFAs
metabolism has also been postulated to occur in chil-
dren suffering from attention-deficit hyperactivity
Table 1 Mean ± S.D of LA/AA, ALA/DHA, AA/DHA, EPA/
DHA and EPA/AA ratios in plasma of autistic patients (N
= 25) compared to age- matching controls (N = 16).
Parameters Groups Min. Max. Mean ± S.D P value
LA/AA Control 0.48 1.02 0.62 ± 0.16 0.034
Autistic 0.41 3.31 1.08 ± 0.90
ALA/DHA Control 0.17 1.26 0.59 ± 0.36 0.004
Autistic 0.43 1.18 0.84 ± 0.19
AA/DHA Control 0.47 0.99 0.81 ± 0.17 0.000
Autistic 0.19 0.61 0.33 ± 0.14
EPA/DHA Control 0.17 1.44 0.56 ± 0.39 0.576
Autistic 0.42 1.07 0.61 ± 0.19
EPA/AA Control 0.24 1.46 0.66 ± 0.37 0.000
Autistic 1.01 3.49 0.96 ± 0.20
Fatty acids are expressed in mmol/L plasma. Significant level at p < 0.01
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dren, particularly boys, who are inattentive, impulsive
and hyperactive [34]. Moreover, Mitchell et al. (1987)
[35] and Stevens et al (1995) [36] showed that the pro-
portions of DHA and AA were significantly lower in the
plasma of ADHD children. They recorded that approxi-
mately 40% of subjects with ADHD had a greater fre-
quency of symptoms indicative of EFAs deficiency
(increased thirst, frequent urination, high fluid
consumption, dry hair), compared to age- matching
controls. The decreased levels of AA and DHA reported
in the present study may be caused by increased activity
of phospholipase A2 [19].
Autism exhibits a marked gender bias with approxi-
mately four times more males diagnosed than females
[37]. Although prepubertal boys and girls have similar
testosterone levels (3.9 vs. 4.7 ng/dL) [38], prepubertal
girls have 8-fold higher levels of estrogen than prepu-
bertal boys (0.6 vs. 0.08 pg/mL [39]. Estrogen is neuro-
protective against glutamate-induced neurotoxicity
[40,41]. Further evidence regarding the protective char-
acteristics of circulating estrogen levels comes from the
work of Djouadi and colleagues (1998) [42]. Extier et al.
(2009) [43] strongly suggest that male testosterone
down- regulates while female estradiol up-regulates the
synthesis of long chain n-3 PUFAs from ALA. This
information could be helpful to suggest that deficiency
of AA and DHA in Saudi autistic patients is greatly con-
tributed in the etiology of the disorder.
Table 1 also demonstrates a much lower AA/DHA in
autistic patients of Saudi Arabia compared to age-
matched control. This could be attributed to a combina-
tion of factors including altered enzyme activity affecting
conversion of LA and ALA as precursor fatty acids and/
or excessive utilization of these metabolites. The
Table 2 Mean ± S.D of plasma levels of PC, PS and PC (expressed in mmol/L plasma) in autistic patients compared to
age- matching controls.
Parameter Group N Minimum Maximum Mean ± S.D P value
PE Control 16 0.022 0.059 0.043 ± 0.010 0.002
Autistic 25 0.021 0.063 0.032 ± 0.009
PS Control 16 0.065 0.099 0.081 ± 0.009 0.000
Autistic 25 0.034 0.067 0.051 ± 0.009
PC Control 16 1.369 1.979 1.711 ± 0.185 0.000
Autistic 25 0.862 1.989 1.313 ± 0.333
Significant level at p < 0.005
0.000
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0.020
0.030
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Control Autistic
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Figure 1 Mean of measured phospholipids in autistic (N = 25)
compared to age- matching controls (N = 16). Mean value for
each group is designated by a line. (a) PE; (b) PS and (c) PC.
Table 3 ROC analysis of LA/AA, ALA/DHA, AA/DHA, EPA/
DHA and EPA/AA ratios and PE, PS and PC in autistic
groups (N = 25).
Parameter Area under the
curve
Cutoff
value
Sensitivity
%
Specificity
%
LA/AA 0.592 0.69 60.0% 84.6%
ALA/DHA 0.713 0.57 90.9% 61.5%
AA/DHA 0.977 0.66 100.0% 84.6%
EPA/DHA 0.658 0.39 100.0% 46.2%
EPA/AA 0.937 1.07 93.8% 84.6%
PE 0.806 0.037 80.0% 75.0%
PS 0.998 0.068 100.0% 93.7%
PC 0.825 1.619 80.0% 75.0%
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in autistic patient could be also explained on the basis
that within body tissues, DHA status fluctuates quite
readily with dietary changes while AA concentrations
remain relatively stable and that there is little difference
in AA content amongst individuals [44]. Therefore, the
occurrence of a subnormal AA concentration in Saudi
autistics [El-Ansary A, Ben Bacha A, Al-Ayadhi L:
Plasma fatty acids as diagnostic markers in autistic
patients from Saudi Arabia, Submitted.] may be of parti-
cular importance than DHA and could be physiologi-
cally relevant to abnormal brain function. Table 1 also
showed that autistic patients had a significantly higher
EPA/AA ratio which confirmed that they have much
higher n-3/n-6 fatty acids. This is in good agreement
with the previous reports of Wiest et al. (2009) [45] that
individuals with autism had higher concentrations of
long-chain n-3 fatty acids in both PE and PC, and
tended to have lower concentrations of long-chain n-6
fatty acids. They attributed this elevated ratio to the fact
that plasma lipid profiles are known to be affected by
increased consumption of n-3-rich food e.g fish, raising
EPA and DHA.
Consistent with the increased oxidative stress biomar-
kers, Saudi children with autism were found to have
increased body burdens of lipid peroxides [46]. A sec-
ond line of evidence that oxidative stress may play a
role in autism in Saudi population is suggested by a
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Figure 2 ROC curves showing area under the curves, specificity and sensitivity of LA/AA (a), ALA/DHA (b), AA/DHA (c), EPA/DHA (d)
and EPA/AA (e), PE (f), PS (g) and PC (h) in autistic patients (N = 25).
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Page 5 of 9reduced endogenous antioxidant capacity. Specifically,
altered glutathione peroxidase (GPX), superoxide dismu-
tase (SOD), catalase activities as well as total GSH and
vitamin E [46]. Lower AA concentration recorded in the
present study could be easily related to the oxidative
stress as an accepted mechanism in the etiology of aut-
ism. This suggestion could be supported through con-
sidering the previous work of Ming et al. (2005) [47] in
which they recorded urinary excretion of 8-isoprostane
(8-iso-PGF2a) a class of autoxidation products generated
from AA acid by a free radical initiated process, in chil-
dren with autism compared to age-matched controls.
In eukaryotic cells, phospholipids are the predominant
membrane lipids and are, from a topographic point of
view, asymmetrically distributed across the bilayer
[48,49]. PC, PE, PS, are the major phospholipids [50]. In
most eukaryotic membranes, PC and PE represent
together around 60-85% of the phospholipids fraction,
while for the other phospholipids small but significant
differences can be found depending of the cell mem-
brane and even animal species [51,52]. Phospholipids
play multiple roles. They constitute a permeability bar-
rier, modulate the functional properties of membrane-
associated activities, provide a matrix for the assembly
and function of a wide variety of catalytic processes, and
a c ta sd o n o r sd u r i n gt h es y n t hesis of macromolecules.
The wide range of processes in which phospholipids are
specifically involved explains the need for diversity in
phospholipid structures and fatty acid composition [53].
Table 2 and Figure 1 demonstrated that PE, PS and
PC were significantly lower in autistic patients com-
pared to healthy control. This could be easily corre-
lated to certain autistic features specially those related
to oxidative stress and inflammatory responses as two
mechanisms have been shown to play a critical role in
the pathophysiology of autism. This could find a
  1 
 
 
 
 
 
 
(b)  (a) 
(c) 
(e) 
(d) 
(f) 
Figure 3 Correlation between the measured phospholipids and fatty acids ratios for autistic patients (N = 25) with best fit line curve:
(a) PE and AA/DHA (positive correlation); (b): PE and EPA/AA (negative correlation); (c): PS and AA/DHA (positive correlation); (d): PS and EPA/
AA (negative correlation); (e): PC and AA/DHA (positive correlation); (f): PC and EPA/AA (negative correlation).
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al. (2009) [54] that Omega-6 phospholipids, e.g. PC
have been shown to have anti-inflammatory properties
through inhibiting tumor necrosis factor (TNF-a)a n d
H2O2 activated mitogen-activated protein kinase
(MAPK) in neuronal cell line SH-SY5Y cells and pre-
vents the phosphorylation and activation of nuclear
factor-kappa B. The lower concentration of PC
reported in the present study could explain the pre-
viously proved H2O2 intoxication in plasma samples
collected from the same autistic patients [46] and
explain the increase of pro-inflammatory cytokines in
autistic patients [55].
The obtained lower PS presented in Table 2 and Figure
1 in plasma of autistic patients compared to age- matching
controls could be easily correlated to the over expression
of superoxide dismutase (SOD) as a phenotype previously
reported by Al-Gadani et al. (2009) [46] in autistic patients
from Saudi Arabia. Glozman et al. (2000) [56] proved that
Cu/Zn-SOD gene are compatible with DHA and PS defi-
ciency in the fetal, but not the adult brain.
It is well documented that phospholipids enriched in
unsaturated fatty acids (PE, PS and PC) are crucial to the
normal neurological function of the brain. Neurodegen-
eration has been shown to be associated with abnormal
phospholipids metabolism in the brain [57]. Erythrocyte
membrane phospholipid composition has been shown to
correlate to brain phospholipid composition [58] and
may be a useful marker for neurological disease [59,60].
ROC analysis presented in table 3 together with figure
2 demonstrate that AA/DHA, EPA/AA and the three
measured phospholipids (PE, PS and PC) showed a
satisfactory specificity and sensitivity and they could be
uses as biomarkers for the early diagnosis of autism in
Saudi populations.
Figure 3 demonstrate the Pearson correlation test
between fatty acid ratios and phospholipids concentra-
tions. PE, PS and PC are correlated negatively with
EPA/AA and positively with the AA/DHA which high-
light the relationship between AA deficiency and the
etiopathology of autism. This support the previously
mentioned phenomena that subnormal concentration of
AA is more related to autism than DHA and EPA as
two PUSFAs greatly affected by diet.
In conclusion, since erythrocyte phospholipid compo-
sition is impacted by dietary habits, the therapeutic early
administration of omega-6 phospholipids, such as PC,
would be expected to increase the concentration of
these lipids in both the plasma and brain and promote
neuronal anti-inflammatory events.
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